Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2019 | 2 |
2021 | 3 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Budget Impact of Dabrafenib and Trametinib in Combination as Adjuvant Treatment of BRAF V600E/K Mutation-Positive Melanoma from a U.S. Commercial Payer Perspective.
J Manag Care Spec Pharm. 2019 Nov;25(11):1227-1237. doi: 10.18553/jmcp.2019.25.11.1227.
J Manag Care Spec Pharm. 2019.
PMID: 31663466
Free PMC article.
Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2- Advanced Breast Cancer.
Stellato D, Thabane M, Eichten C, Delea TE.
Stellato D, et al.
Curr Oncol. 2021 Jan 14;28(1):491-508. doi: 10.3390/curroncol28010051.
Curr Oncol. 2021.
PMID: 33466914
Free PMC article.
Item in Clipboard
Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective.
Stellato D, Thabane ME, Park J, Chandiwana D, Delea TE.
Stellato D, et al.
Pharmacoeconomics. 2021 Sep;39(9):1045-1058. doi: 10.1007/s40273-021-01027-4. Epub 2021 Jun 9.
Pharmacoeconomics. 2021.
PMID: 34105083
Item in Clipboard
Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2- Advanced Breast Cancer: A Canadian Healthcare Perspective.
Stellato D, Thabane ME, Chandiwana D, Park J, Delea TE.
Stellato D, et al.
Pharmacoeconomics. 2021 Jul;39(7):853-867. doi: 10.1007/s40273-021-01028-3. Epub 2021 May 18.
Pharmacoeconomics. 2021.
PMID: 34002341
Item in Clipboard
Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective.
Gerbasi ME, Stellato D, Ghate SR, Ndife B, Moynahan A, Mishra D, Gunda P, Koruth R, Delea TE.
Gerbasi ME, et al. Among authors: stellato d.
J Med Econ. 2019 Dec;22(12):1243-1252. doi: 10.1080/13696998.2019.1635487. Epub 2019 Aug 4.
J Med Econ. 2019.
PMID: 31223037
Free article.
Item in Clipboard
Cite
Cite